Antisense cancer therapies - Market Research Reports

Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1083

Antisense cancer therapies

Description:

The development of antisense compounds will provide physicians with a highly efficacious family of compounds exhibiting favorable side-effect profiles. Within this class, Genta''s Genasense is predicted to be the key compound. The development of antisense therapeutics provides a rapid discovery-to-laboratory time frame that would suit the limited cash resources of the biotechnology sector and provides substantial innovative pipeline-building potential. However, the success of this class of compounds is largely dependent on the level of skepticism the physicians and the pharmaceutical industry holds upon the initial product launches, and how well they individually perform in the clinic. This report discusses the rise of the antisense therapeutic in cancer, and the skepticism surrounding the class’ history, whereby a successful product launch has the potential to create a new wave of therapy evolution.

Contents:

TABLE OF CONTENTS

EXECUTIVE SUMMARY

INTRODUCTION

The antisense mechanism

Types of oligonucleotides

How oligonucleotides are placed in the cells

The history of antisense as a therapeutic: a rocky ride of skepticism

DEVELOPMENTAL ANTISENSE PRODUCTS IN CANCER

Phase III compounds

Genasense (augmerosen/G3139)

LY900003 (ISIS 3521)

Phase II compounds

ISIS 2503

Phase I Compounds

OGX-011 (ISIS 112989)

LE-AON/LEraf-AON (liposome ecapsulated c-raf antisense oligonucleotide/ISIS-5132)

MG98

COMPETITIVE ANALYSIS

CONCLUSIONS AND SUMMARY

REFERENCES

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/1083

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2
Printed 05/12/2008 09:51:35

Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com

Order information

Please verify that the product information is correct and select the format you require.


Product Name:
Antisense cancer therapies
Web Address:
http://www.researchandmarkets.com/reports/1083
Office Code:
OCIFKHQLOUZ

Report formats

Please enter the quantity of the report format you require.

Format	Quantity	Price
Hard Copy		€1,669.00 + EUR€ 50.00 Shipping/Handling *
Electronic		€2,033.00
Electronic - Site License		€1,605.00

* Shipping/Handling is only charged once per order.

Contact information

Please enter all the information below in BLOCK CAPITALS.


	First Name:	Last Name:
	Email Address:
	Job Title:
	Organisation:
	Address:
	City:
	Postal/Zip Code:
	Country:
	Phone Number:
	Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World

Page 2 of 2
Printed 05/12/2008 09:51:35

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

	American Express
	Diners Club
	Master Card
	Visa


Cardholder Name:

Expiry Date:	/

Card Number:

CVV Security Code:

Issue Date:	/ (Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:


Account number:	83313083
Sort code:	98-53-30
Swift code:	ULSBIE2D
IBAN number:	IE78ULSB98533083313083
Bank Address:	Ulster Bank, 27-35 Main St, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:
	Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World